Jun 28, 2021
Vivpro Announces New Appointment To Board Of Advisors: Dr. Bev Incledon
Vivpro Corporation announced today that it has appointed Dr. Bev Incledon, EVP and Chief Scientific Officer, Ironshore Pharmacuticals Inc. to its Advisory Board.
”We are pleased to welcome Bev to the Vivpro Advisory board,” said Dr. Joga Gobburu, President Vivpro Corporation. ”Bev’s deep experience in pharmaceutical development will be invaluable to Vivpro as we grow our business and pursue our mission to re-imagine drug development. Bev is a founding member of the Vivpro Advisory Board. Vivpro advisory board is a critical step in our journey as we enter a new stage of product growth, we would like to work with passionate individuals like Bev to validate and guide our niche market strategy and customer value.”
This is one of several appointments that will be announced over the next few weeks. Vivpro will regularly evaluate the membership to ensure it includes diverse skills, experience and perspective necessary to drive growth for all Vivpro customers.
”I am excited to join Vivpro advisory board and believe that Vivpro is uniquely qualified to help speed up drug development by retrieving quality data in the most efficient manner possible,” said Dr. Bev Incledon.
About Dr. Bev Incledon
Dr. Incledon serves as the Chief Scientific Officer for Ironshore Pharmaceuticals and Development INC. Dr. Incledon has over 28 years of pharmaceutical industry experience encompassing large and small molecule drug discovery, pre-clinical, clinical, product and manufacturing process development roles as well as new R&D facility start-up, and research on novel drug delivery technology. Dr. Incledon gained these experiences through roles with increasing responsibility at Syntex Inc., Glaxo Wellcome Inc., Eli Lilly and Company and several start up biotech companies before joining Ironshore. Over his career he has been a contributor to 21 clinical development stage and 8 marketed products.
